CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Atavistik Bio›
News
Atavistik Bio logo

Atavistik Bio

Atavistik Bio: Pioneering pre-clinical biotech firm developing first-in-class drug candidates.

Cambridge, MA, US🇺🇸
Founded
2021
Loading
Overview
Compare
Fundraising
Employees
News
Library

Latest News About Atavistik Bio

Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics

Atavistik Bio

Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics

Atavistik Bio announced a research collaboration with Roche to develop allosteric small molecules for cardiovascular, renal and metabolic...

Sep 24, 2026

Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia

Atavistik Bio

Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia

Atavistik Bio joined the Cure HHT Clinical Trial Network to support development of ATV-1601. The company also reported activating the first...

Jul 30, 2026

Atavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Atavistik Bio

Atavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Atavistik Bio announced FDA clearance of the investigational new drug application for its Harmony-HHT Phase 1/2 study and Fast Track...

Jun 9, 2026

Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million

Atavistik Bio

Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million

Atavistik Bio closed a $40 million extension to its Series B financing, bringing the round to $160 million. New investor RA Capital joined...

Mar 5, 2026

Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics

GlobeNewswire

Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics

Atavistik Bio and Pfizer agreed to collaborate on precision allosteric therapeutics. The partnership brings the biotechnology company's...

Jan 2, 2025